Head and neck squamous cell carcinoma (H&N SCC) incorporate tumours of varying areas of the upper aerodigestive tract,including the larynx,hypopharynx,nasopharynx,and oropharynx. H&N cancer is increasingly common in the UK,with rates increasing by 34% since the early 1990s. The rising prevalence of H&N cancer has been attributed to a rising rate in women,and the prevalence of the Human papilloma virus (HPV) in oropharyngeal cancer,which can account for up to 70% of cases. The survival in H&N cancer is highly variable,ranging from over ...

GO TO STUDY

Primary biliary cholangitis (PBC) is a rare liver disease. A number of treatments exist,which slow the rate that liver disease gets worse. However,at the moment,doctors have to wait for one treatment to fail before adding in a second. As a result,many people with PBC develop symptoms and some go on to need a liver transplant. The aim of the OPERA trial is to see if people who are newly/recently diagnosed with PBC have a better outcome if they receive two medicines ...

GO TO STUDY

AGCT1531 is the first international Phase 3 randomised controlled trial for low and standard risk extra-cranial germ cell tumours (GCT) in children, teenagers and young adults (TYA). Many cancers predominantly affecting TYA patients are considered rare because the incidence is low during early childhood and in older patients. However, GCTs are the third most common cancer diagnosed in the TYA population. Most patients with a GCT can expect cure, however, TYA outcomes are much worse than in children and adults. The trial ...

GO TO STUDY

GT005, a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I, is currently being developed as a potential gene therapy for GA secondary to AMD. Current regulatory guidelines [EMA 2009; EMA 2018; FDA 2020] recommend that participants enrolled in gene therapy clinical trials with viral vectors that are non-replicating, non-integrating, and have no known potential for latency and re-activation should be followed for approximately 5 years post-treatment. The aim of this study (GT-ORACLE) is to evaluate ...

GO TO STUDY

Surgery remains the best option for the cure of patients with lung cancer. Around 7000 people in the UK undergo lung surgery each year, but up to 45% of patients developed post-operative complications leading to readmission to hospital and potentially poorer quality of life. National and international cancer, surgery and nutrition guidelines recommend a combination of exercise and nutritional support before and after surgery to help reduce post-operative complications. However it is not clear what is the best way to ...

GO TO STUDY

Breast cancer is the most common cancer worldwide and a leading cause of cancer-related death. Despite improvements in survival rates, a significant number of patients eventually develop distant metastasis after initial treatment. Metastatic breast cancer is difficult to diagnose and current tests including CT, MRIs, and PET scans are expensive and have low throughput. Biomarkers for metastatic cancer require specialised laboratory equipment, yet, their clinical utility is limited. This study aims to investigate the use of a point-of-care test LIT ...

GO TO STUDY

Although the COVID-19 vaccination program has proved extraordinarily successful, clinically vulnerable (CV) patients remain at risk of SARS-CoV-2 infection, severe COVID-19 and death. Large (inter)national studies, have previously identified some patient groups who make sub-optimal immune responses to COVID-19 vaccines, and those at highest risk of severe COVID-19. Although the precise immune correlates of protection against severe COVID-19 are not defined, recent emerging data in patient groups suggests that the serological response to vaccination is a critical determinant in ...

GO TO STUDY

This study is looking at the best way to confirm the presence of an eye condition known as neovascular age-related macular degeneration (nAMD), a common condition that affects vision. nAMD usually affects people in their 50s and 60s, and diagnosis is confirmed by examining the back of the eye. There are a number of ways of doing this, the most common being Fluorescein Angiography (FA) where any leakage of a fluorescent dye over several minutes is detected by a special ...

GO TO STUDY

mRNA-4359 alone or in combination with pembrolizumab dependent on which arm the participant is assigned. mRNA-4359 dosing: mRNA-4359 will be given at the study site by injection into shoulder or thigh muscle (intramuscular [IM] injection) once every 3 weeks (Day 1 of every cycle). Up to 9 doses of mRNA-4359 will be given in this study, over an approximately 6-month period. Pembrolizumab dosing: If taking pembrolizumab in combination with mRNA-4539, pembrolizumab will be given at the study site by infusion into ...

GO TO STUDY

The primary objective is to determine whether there is a cyclical component to hypercortisolaemia in all patients diagnosed with endogenous Cushing’s syndrome. The secondary objective is to study post-operative CS patients who have features of CS recurrence and also to study patients with strong clinical suspicion for CS but no test is confirming the diagnosis. Study question in this group: how long should patients be monitored before it can be concluded that the patient does not have CS.

GO TO STUDY